Choose your next compounds with more of the picture.
Screen absorption, distribution, metabolism and safety in one ADMET workflow. Compare liabilities before committing your next assay budget.
Screen absorption, distribution, metabolism and safety in one ADMET workflow. Compare liabilities before committing your next assay budget.
Review permeability, binding, metabolism and safety signals before advancing a candidate.
See where a compound performs well and where the next experiment should focus.
Use interactive predictions or connect the ADMET workflow to your existing screening tools.
96 public test compounds · identity, fingerprint and scaffold references excluded.
0.952 with identity/fingerprint exclusions only; same 96 cases.
Current alternative mode on the 182-case known development panel. Profile mode: 0.914 under its separate reference exclusions.
CYP3A4 · 2,467 reference-excluded test cases; AUPRC 0.814.
CYP2C9 AUROC 0.835; CYP2D6 0.821. Full endpoint results in the benchmark.
Caco-2 permeability, blood-brain barrier classification, aqueous solubility and plasma protein binding.
Intrinsic-clearance and metabolic-stability estimates, plus per-isoform CYP inhibition predictions.
hERG inhibition estimates and DILI risk, with mechanism and exposure context.
Each endpoint retains its own input and measured scope. Explore the complete performance tables.
Tell us which compounds, endpoints and decisions matter. Build a focused pilot around your workflow, with agreed outputs and success criteria.